Recent studies have indicated that CCT3 overexpression may influence tumor progression through the JAK–STAT3 pathway.[23,34] Danni et al[24] confirmed that silencing CCT3 can sensitize lung cancer cells to cisplatin by inhibiting the JAK2–STAT3 pathway, suggesting that CCT3 could be a novel target for overcoming cisplatin resistance in lung cancer patients. Here, JAK2 is linked to lung carcinoma.